Inhaled Cannabis
Phase 1Small molecule
Inhaled Cannabis is one of 31 small molecule programs targeting Multiple Sclerosis. It is currently in Phase 1.
2
Indications
2
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Betaseron
BayerPreclinical
Kesimpta
NovartisPreclinical
Tysabri
BiogenPreclinical
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Myfortic
NovartisPreclinical
Novantrone
PfizerPreclinical
Pred Forte
NovartisPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Inhaled Cannabis. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of California, Davis